Saturday, November 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Sangamo Therapeutics Secures Crucial Funding Amid Mixed Results

SiterGedge by SiterGedge
April 5, 2026
in Analysis, Earnings, Healthcare, Pharma & Biotech, Turnaround
0
Sangamo Therapeutics Stock
0
SHARES
62
VIEWS
Share on FacebookShare on Twitter

Sangamo Therapeutics finds itself navigating a complex landscape of operational progress against a backdrop of challenging financial performance. Recent developments highlight both the company’s scientific momentum and the persistent pressure on its balance sheet, with a significant capital infusion providing a critical runway.

Financial Performance and Capital Raise

The company’s fourth-quarter 2025 results revealed significant headwinds. Revenue came in at $14.23 million, falling substantially short of market expectations, which were above $40 million. The net loss per share was $0.11, double the amount analysts had projected.

However, a key positive emerged from Sangamo’s efforts to bolster its finances. Since the beginning of 2025, the biotech firm has secured a total of $130 million in capital. This liquidity injection, sourced from licensing fees, milestone payments, and equity financing, provides essential breathing room to advance its clinical programs.

Regulatory and Clinical Pipeline Advances

Operationally, Sangamo has achieved important regulatory milestones. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate SC503 for neuropathic pain. This status is designed to expedite the development and review process for promising therapies.

Should investors sell immediately? Or is it worth buying Sangamo Therapeutics?

Concurrently, the company has initiated a rolling submission for the biologics license application (BLA) of ST-920, its investigational treatment for Fabry disease. The clinical rollout continues, with six active sites currently enrolling patients for the pivotal STAN study. These steps underscore continued pipeline advancement despite financial constraints.

Divergent Analyst Perspectives

Market experts are divided in their assessment of Sangamo’s outlook. Investment firm HC Wainwright maintains a Buy rating on the stock, with a price target of $10.00. While the analysts slightly adjusted their long-term earnings estimate for fiscal year 2028 from $0.28 to $0.27 per share, their overall view on the company’s potential remains favorable.

The broader analyst consensus is more cautious, reflecting the recent earnings miss and ongoing challenges:
* Consensus Rating: Hold
* Average Price Target: $5.50
* Institutional Ownership: 56.9%
* Market Capitalization: Approximately $101 to $124 million

The $130 million in secured funding buys Sangamo valuable time to drive the ST-920 approval process forward. Investor attention is now firmly fixed on upcoming data readouts from the STAN study, which will be pivotal in determining the long-term viability of the company’s therapeutic platform.

Ad

Sangamo Therapeutics Stock: Buy or Sell?! New Sangamo Therapeutics Analysis from November 21 delivers the answer:

The latest Sangamo Therapeutics figures speak for themselves: Urgent action needed for Sangamo Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

Sangamo Therapeutics: Buy or sell? Read more here...

Tags: Sangamo Therapeutics
SiterGedge

SiterGedge

Related Posts

SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Nvidia Stock
AI & Quantum Computing

Nvidia’s Insider Sales and $12.9 Billion Acquisition Paint a Portrait of a Company in Overdrive

September 7, 2026
Next Post
Netflix Stock

Netflix Faces Pivotal Earnings Amid Price Hikes and Trade Uncertainty

Primeumber Acquisition IUnit Stock

noco-noco's Uphill Battle to Regain a Major Exchange Listing

Uranium Energy Stock

Uranium Energy's Strategic Shift: Building an Integrated Nuclear Fuel Supplier

Recommended

Hellofresh Stock

A Vote of Confidence: HelloFresh Insider Buys Amid Steep Share Decline

8 months ago
Ondas Holdings Stock

Ondas Holdings Strengthens Defense Sector Ambitions with Key Board Appointment

9 months ago
Lincoln National Stock

Lincoln National’s Q2 Earnings Beat Overshadows Revenue Concerns

1 year ago
TKMS Stock

TKMS Nears Final Approval for Landmark Indian Submarine Contract

8 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

Trending

Nvidia Stock
Newsletter

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

by Stephanie Dugan
November 20, 2026
0

Dear readers, Yesterday's open question was whether the largest IPO on record could steady a falling tech...

Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026
Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News
  • Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com